Phase 1/2 Trial of CAR-T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer – Cancer Therapy Advisor
Cancer Therapy Advisor |
Phase 1/2 Trial of CAR–T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer
Cancer Therapy Advisor Description: For this open-label, single-group assignment phase 1/2 study (ClinicalTrials.gov Identifier: NCT01583686), researchers are evaluating whether chimeric antigen receptor (CAR)-T cell immunotherapy that targets mesothelin is safe and … |
